Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Visual outcomes and real life performance of bilaterally implanted extended vision intraocular lens: a prospective study

Poster Details

First Author: A.Sharma INDIA

Co Author(s):    S. Goel                    

Abstract Details

Purpose:

To study the performance of bilaterally implanted extended vision Symfony IOL in terms of1. Postoperative unaided distance(UDVA) , intermediate (60cm) (UIVA), near visual acuity(33cm) (UNVA)2. Post operative Contrast senstivity3. Photic phenomenon ((Glare, halos, starburst if any)4. Subjective patient and surgeon satisfaction score ( 0 to 10)

Setting:

Eye Q Superspeciality Eye Hosptial, India

Methods:

Multicentric prospective interventional study including 40 patients of bilaterally implanted Symfony /Symfony Toric IOL operated after January 2015.All patients underwent uneventful 2.2 mm incision phacoemulsification surgery. Postoperatively at 1month, 3month and 6 months unilateral and bilateral distance , near and intermediate vision , contrast senstivity were recorded and any complaint of glare or halos was noted

Results:

Mean postoperative UDVA, UIVA and UNVA at 6 months was 0.93, 0.92 and 0.91 respectively. 33 patients had UDVA >/= 1.0 while 36 patients had UIVA >/= 1.0 . UNVA was >/= in 27 patients . Only 7.5% of patients needed glasses for intermediate and near vision in daily activities. 12.5% of patients complained of mild to moderate glare in initial postoperative period that was not significant till last follow up.Mean postoperative binocular contrast senstivity at 6 months was 1.52�Â�±0.12. Patient satisfaction score was 9.5 in terms of unaided range of vision and overall surgeon satisfaction score was 9.0

Conclusions:

Extended vision symfony IOL is efffective in reducing spectacle dependence for all range of vision with good post operative contrast senstivity.

Financial Disclosure:

NONE

Back to Poster listing